The Global liposome drug delivery market is estimated to be valued at US$ 5,482.2 Mn in 2024 and is expected to exhibit a CAGR of 8.9% over the forecast period 2024 To 2031.
Key Takeaways
Key players operating in the liposome drug delivery are Gilead Sciences, Inc., Luye Pharma Group, Ipsen Biopharmaceuticals, Inc., Pacira Pharmaceuticals, Inc., Acuitas Therapeutics, LIPOSOMA B.V., Takeda Pharmaceutical Company Limited, Taiwan Liposome Company, Ltd., Endo International, and Jazz Pharmaceuticals plc. These players are focusing on new product approvals and launches to strengthen their presence in the market.
The growing incidence of cancer and infectious diseases is expected to create significant opportunities for players in the Liposome Drug Delivery Market Size. Liposomes can also facilitate co-delivery of diagnostic agents along with therapeutics thereby improving treatment outcomes.
Technological advancements are further augmenting the potential of liposomes for targeted delivery of diverse drug classes including plasmid DNA, miRNAs, proteins and gene therapy vectors. Active targeted liposomes using ligands help in overcoming physiological barriers and enhancing drug accumulation at target sites.
Market Drivers
The rising demand for targeted drug delivery approaches to minimize toxicity and improve the efficacy of anti-cancer medications is a key driver for the liposome drug delivery market. Growing pipeline of liposomal drug formulations and their increasing commercialization further supports market growth. In addition, continuous advancements in liposomal formulation technologies help expand the applications of liposomes to various therapeutic areas including infectious diseases, autoimmune disorders and dermatology.
Current Challenges in the Liposome Drug Delivery Market
The liposome drug delivery market faces several key challenges. Developing an efficient and stable formulation is difficult due to the complex interaction between the drug and phospholipid bilayer of liposomes. Ensuring optimal drug loading and retaining drug inside the liposomes during circulation is another major challenge. Leakage of encapsulated drug before reaching the target site can limit the therapeutic efficacy. Development of targeted liposomes able to efficiently deliver drugs to desired cells/tissues selectively also requires extensive research. High costs associated with manufacturing, scale-up and stability testing of liposomal formulations pose commercial challenges.
Get more insights on Liposome Drug Delivery Market
